about
Industrialization of mAb production technology: the bioprocessing industry at a crossroadsProduction of monoclonal antibodies in plants for cancer immunotherapyNucleic Acid Aptamers: An Emerging Tool for Biotechnology and Biomedical SensingAlgae as protein factories: expression of a human antibody and the respective antigen in the diatom Phaeodactylum tricornutumRibosome display: next-generation display technologies for production of antibodies in vitro.Production of a recombinant mouse monoclonal antibody in transgenic silkworm cocoons.Optimized expression of full-length IgG1 antibody in a common E. coli strain.A novel platform to produce human monoclonal antibodies: The next generation of therapeutic human monoclonal antibodies discovery.Characterization of a human monoclonal antibody against Shiga toxin 2 expressed in Chinese hamster ovary cells.Generation and Characterization of a scFv Antibody Against T3SS Needle of Vibrio parahaemolyticusSuppression of Aggrus/podoplanin-induced platelet aggregation and pulmonary metastasis by a single-chain antibody variable region fragmentEngineered antibody variable and constant domains as therapeutic candidates.Strategies for efficient production of heterologous proteins in Escherichia coli.The Structural Role of Antibody N-Glycosylation in Receptor InteractionsTransgenic plants in the biopharmaceutical market.Recombinant snakebite antivenoms: A cost-competitive solution to a neglected tropical disease?Efficient antibody production upon suppression of O mannosylation in the yeast Ogataea minutaDevelopment of recombinant human polyclonal antibodies for the treatment of complex human diseases.Immunoglobulin domains in Escherichia coli and other enterobacteria: from pathogenesis to applications in antibody technologies.Immunotherapeutic approaches in prion disease: progress, challenges and potential directions.Bioreactor productivity and media cost comparison for different intensified cell culture processes.Plantibodies in human and animal health: a review.Efficient expression from one CMV enhancer controlling two core promoters.Evaluation of eco-friendly zwitterionic detergents for enveloped virus inactivation.Single-batch production of recombinant human polyclonal antibodies.An engineered diatom acting like a plasma cell secreting human IgG antibodies with high efficiency.Engineering and characterization of the chimeric antibody that targets the C-terminal telopeptide of the α2 chain of human collagen I: a next step in the quest to reduce localized fibrosis.SEAP expression in transiently transfected mammalian cells grown in serum-free suspension culture.Remarkable alkaline stability of an engineered protein A as immunoglobulin affinity ligand: C domain having only one amino acid substitution.Designing Human Antibodies by Phage DisplayPotential aggregation prone regions in biotherapeutics: A survey of commercial monoclonal antibodies.High yield of human monoclonal antibody produced by stably transfected Drosophila schneider 2 cells in perfusion culture using wave bioreactor.Optimizing assembly and production of native bispecific antibodies by codon de-optimization.Transient expression in tobacco leaves of an aglycosylated recombinant antibody against the epidermal growth factor receptor.Isolation, characterization, and molecular modeling of a rheumatoid factor from a Hepatitis C virus infected patient with Sjögren's syndrome.
P2860
Q24655304-5A5F79A6-1058-4224-9655-D90E941F20E5Q26778423-393E16A2-AA9D-4273-8DB2-E2340C81532AQ26825644-0440CE49-F5BA-46CB-8CF1-A29DC190CF2EQ28742000-ACD37D73-9CC1-4DDB-ABA1-304739EF5581Q33218320-B72FAB65-BECB-494A-AEB7-33F292EE058CQ33501332-11F1802D-3D50-439B-8BBF-681B5EEBBC22Q33565621-ADA62105-91CE-4959-B086-4B24782B6FABQ33810163-88804314-CDA7-44F5-B5A8-FF7FD7FBF02BQ33883354-B58AFB38-2B79-4101-9091-5A2917F6C9F1Q34301243-1562A870-6A16-4EB8-B522-51EE9463068FQ34982597-2D09AC6F-9FA2-4D07-8146-3879DF805D49Q35044156-2998071D-6D4F-4044-A2BB-D70F6919B715Q36001048-CBE1D54B-DE2B-44B9-A12B-945229050AB0Q36021825-B5C8B131-5341-4D0F-999C-EB3D5AC23A64Q36066053-C2C1E8ED-38AA-42E8-AB33-288989FD9EC9Q36269593-C48DCCC6-769A-4616-A06C-AB793F9B6B48Q36420948-892527D5-F2E9-4F59-AFE8-DACB76BC1161Q36569741-900D0D9B-4DCE-4957-9627-96D5F48D441BQ38020872-A296DE8B-2CAE-4A17-9FA8-751CB41034B7Q38104409-9C97C300-F88A-46BE-B08A-10129E13F41DQ38726126-CBC6574A-E561-4AD4-BE49-9E9DDCCCDFB2Q38949097-B2886C1A-D206-487C-903F-B81E01049FF6Q39626455-922AE199-8AB1-483A-AD41-048F62A96386Q40500491-5800E4BF-950C-420F-9C0B-94982E362AFAQ40898112-8AF4A52F-95F1-442D-8A0E-9B823D2EB47BQ41694249-A0602723-CB81-4AFC-8369-9F186F08A9B2Q41881369-3874A7EE-9DB1-4F54-88BD-870A199BCDC5Q42326871-8EC7ABBB-8EFF-4EEA-B3AB-5A417D84AB14Q42632117-365784A6-F56B-43D2-BFBF-1B80F5ECC58DQ42660134-0F88BC9C-3FCC-4EC6-AC82-812047EC85C5Q43070206-6D920F7F-3E40-4EAB-B727-FB267D5B2B6BQ44925086-AF52FDE2-4847-42EA-8691-90341C2E9378Q51070209-93D9A1D5-F8FF-42E2-B0C8-892D393A892DQ51570810-87249C43-F20B-4C5B-84D6-7BF2851ED473Q51850819-A62FDAE3-072F-4469-8CBC-1EA8BE2783E5
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Therapeutic antibody expression technology.
@ast
Therapeutic antibody expression technology.
@en
type
label
Therapeutic antibody expression technology.
@ast
Therapeutic antibody expression technology.
@en
prefLabel
Therapeutic antibody expression technology.
@ast
Therapeutic antibody expression technology.
@en
P1476
Therapeutic antibody expression technology.
@en
P2093
P304
P356
10.1016/S0958-1669(00)00198-1
P577
2001-04-01T00:00:00Z